Cencora, Inc. (NYSE:COR) EVP Silvana Battaglia Sells 5,000 Shares

Cencora, Inc. (NYSE:COR) EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Silvana Battaglia also recently made the following trade(s):

• On Friday, December 20th, Silvana Battaglia sold 1,678 shares of Cencora stock. The stock was sold at an average price of $228.72, for a total value of $383,792.16.

Cencora Trading Up 2.6 %

Shares of Cencora stock opened at $250.59 on Wednesday. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $262.26. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The business has a 50-day moving average price of $240.27 and a 200-day moving average price of $237.56. The firm has a market cap of $48.60 billion, a price-to-earnings ratio of 35.65, a PEG ratio of 1.31 and a beta of 0.49.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date is Friday, February 14th. Cencora’s payout ratio is 31.29%.

Analysts Set New Price Targets

Several research firms recently issued reports on COR. Barclays increased their target price on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Robert W. Baird increased their price objective on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. UBS Group lifted their target price on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Wells Fargo & Company increased their price target on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Finally, JPMorgan Chase & Co. boosted their price objective on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and a consensus price target of $277.90.

Hedge Funds Weigh In On Cencora

Several institutional investors have recently bought and sold shares of COR. JFS Wealth Advisors LLC raised its position in shares of Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after buying an additional 46 shares in the last quarter. Banque Transatlantique SA bought a new stake in Cencora during the fourth quarter worth approximately $29,000. Concord Wealth Partners purchased a new stake in Cencora during the third quarter valued at approximately $30,000. SBI Securities Co. Ltd. bought a new stake in shares of Cencora in the 4th quarter valued at approximately $30,000. Finally, Householder Group Estate & Retirement Specialist LLC boosted its holdings in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after purchasing an additional 69 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.